NRAS and acute myeloid leukemia: Our data showing that K-RasG12D protects MOLM-13 KRASKO cells from apoptosis upon AC220 exposure align with findings from studies of human patients with AML, showing that NRAS and KRAS mutations cause adaptive resistance to clinical FLT3 inhibitors (37).